Additionally, we aimed to evaluate A49G polymorphism in exon 1 and C1858T transition of PTPN22 gene in a group of patients with the onset of AT during INF-α therapy for HCV as compared to subjects without any impairment of thyroid function during treatment. The gene discussed is PTPN22; the disease is ataxia telangiectasia.